Cutera

Cutera, Inc. engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cutera reports strong 2022 performance with focus on AviClear growth

Cutera's performance in 2022 showcased resilience and growth potential, driven by the successful AviClear launch. While facing revenue challenges in Q4 2022, the company is optimistic about achieving cash flow breakeven by Q4 2023. With a bullish outlook for 2023, Cutera aims to leverage its core business strength and accelerate AviClear sales.

Cutera reports Q1 revenue dip, focuses on AviClear growth

Cutera faces challenges in North American sales but sees growth opportunities internationally and with AviClear devices.
Financials show a loss in adjusted EBITDA and decreased cash, but the company is focused on improving execution and driving utilization rates.
Retention incentives have been effective, and steps are being taken to enhance performance and return to sustainable growth.

Cutera reports Q2 revenue decline, focuses on AviClear performance

Cutera reported Q2 2023 revenue of $61.2 million, down 5% YoY, with an adjusted EBITDA loss of $11.6 million. The company is focusing on AviClear performance, quality control, and core business growth.
Challenges include declining core capital business, operational issues, and macroeconomic challenges. Opportunities lie in optimizing AviClear utilization, enhancing reliability, and introducing new products for growth.
Cutera's commitment to addressing challenges, enhancing service levels, and executing a strategic plan for sustainable growth is evident. The organization is resilient in the face of macroeconomic pressures and is adapting its strategies for success.
Retention bonuses, successful employee retention, and efforts to improve quality control measures demonstrate Cutera's internal strengths. The company's strategic approach to product lines and growth showcases a positive outlook for the future.

Cutera reports Q3 revenue decline, focuses on cost reduction

Cutera faces revenue decline and operational challenges in Q3 2023, impacting full-year guidance. Plans for cost reduction, growth strategies, and personnel restructuring in progress. Positive outlook for achieving financial goals with confidence.

Cutera reports Q4 revenue growth, focuses on AviClear expansion

Cutera's Q4 performance reflects resilience with better-than-anticipated revenue and stable AviClear revenue.
Focus on operational excellence, global franchise building, and customer support positions Cutera for long-term success.
Efforts to address challenges like inventory management and customer adoption of new business models are crucial for growth.

Cutera reports mixed Q1 results, focuses on AviClear growth

Cutera's Q1 performance showed a revenue decline but growth in AviClear revenue, with a focus on operational excellence and building a strong AviClear franchise. The company faces challenges with declining customer site volumes and an uncertain timeline for patient demand. However, opportunities exist in international expansion, R&D innovation, and addressing future market needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces their partnership with the Adaptive Training Foundation (ATF), a non-profit organization that provides access and inclusion to individuals living with physical or traumatic impairments empowering them through exercise and community. The Cutera team, with the support of Edward Alvarez, DDS, C.Ac, owner of Madison Avenue Face and Body, has provided ATF participants.

Cutera® Announces Partnership with the Adaptive Training Foundation

Cutera, Inc. (NASDAQ:CUTR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Shelby Eckerman - Vice President of Finance Taylor Harris - Chief Executive Officer Stuart Drummond - Interim-Chief Financial Officer Conference Call Participants Jonathan Block - Stifel Anthony Vendetti - Maxim Group Macauley Kilbane - William Blair Operator Thank you for standing by. This is the conference operator.

Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript

Cutera (CUTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.61 per share a year ago.

Cutera (CUTR) Reports Q3 Loss, Misses Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year gu.

Cutera® Announces Third Quarter 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registrat.

Cutera® to Announce Third Quarter Results on November 7, 2024

Cutera Inc. (CUTR, Financial) experienced a significant stock price decline of 5.14%, bringing its price to $0.751 per share. The trading volume reached 26,733 shares, with a turnover rate of 0.13% and a price fluctuation of 5.03%.

Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges

Cutera, Inc (NASDAQ:CUTR ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Shelby Eckerman - Vice President of Finance Taylor Harris - Chief Executive Officer Stuart Drummond - Chief Financial Officer Conference Call Participants Jordan Bernstein - Stifel Harrison Parson - Stephens James Beer - William Blair Operator Thank you for standing by. This is the conference operator.

Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript

Cutera (CUTR) came out with a quarterly loss of $1.20 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.69 per share a year ago.

Cutera (CUTR) Reports Q2 Loss, Misses Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field se.

Cutera® Announces Second Quarter 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L'Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. "We are excited about this collaboration with L'Oréal Japan Co. to bring SkinCeuticals' renowned skincare innovations to aesthetic provi.

Cutera® Announces Exclusive Distribution Agreement With L'Oréal® for SkinCeuticals® Products in Japan

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link.

Cutera® to Announce Second Quarter Results on August 8, 2024

Coty

e.l.f. Beauty

Celebrity beauty brand stocks can be exceptionally exciting prospects when first looking at them. After all, they have the endorsement of celebrities to build advertising off of, which tends to get people in the door early on.

Investor Alert: 3 Ugly Celebrity Beauty Brand Stocks Not Worth Your Dollar

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June's Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life. Cut.

Cutera® Announces New Survey Data During Acne Awareness Month

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl “Jeri” Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a.

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Micron Technology

Western Alliance Bancorporation

While the rampant speculation that underlines the meme-trading phenomenon may be viewed as problematic, this sector may also provide some hidden gems. The key is to consider fundamentally sound enterprises that happen to be trading below their intrinsic worth.

The 3 Most Undervalued Meme Stocks to Buy in June 2024

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience. The AviClea.

Cutera® Announces AviClear® Investor Webinar

Trupanion

Upstart Holdings

Deep in one of the more passionate and hyperbolic corners of the internet exists a community of investing subReddits. What once existed as a public forum for discussing stock prospects and company valuations has now evolved into several different pockets of speculative fervor.

If You Can Only Buy One Meme Stock Now, It Better Be One of These 3 Names

At a quick glance at its one-year chart, seemingly everything about dermatology specialist Cutera (NASDAQ: CUTR ) screams danger. Typically, a publicly traded firm doesn't lose over 88% of its market value over a 52-week period unless something catastrophic happens.

Trade of the Day: Cutera (CUTR) Stock Presents a Short Squeeze Opportunity

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, granted a total of 44,500 non-qualified inducement stock options to six employees. These awards were approved by the Compensation Committee of Cutera's Board of Directors. The stock options have an exercise price of $2.23, equal to the closing price of Cutera common stock on the grant date of May 13, 2024. A quantity of 25% shall vest annually, a.

Cutera, Inc. Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

SAN FRANCISCO , May 21, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Cutera, Inc. investors that the firm is investigating potential legal claims arising from recent accounting issues, a restatement of the company's financials, and other potential wrongdoing. Current shareholders are encouraged to contact the firm  regarding their rights.

Cutera, Inc. Investor Alert (NASDAQ: CUTR): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors

Cutera, Inc. (NASDAQ:CUTR ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Barker - VP of Finance and IR Taylor Harris - CEO Stuart Drummond - Interim CFO Conference Call Participants George Sellers - Stephens Jon Block - Stifel James Beer - William Blair Nick Sherwood - Maxim Group Operator Thank you for standing by. This is the conference operator.

Cutera, Inc. (CUTR) Q1 2024 Earnings Call Transcript

Cutera (CUTR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.80 per share a year ago.

Cutera (CUTR) Reports Q1 Loss, Tops Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. Consolidated revenue for the first quarter of 2024 of $38.8 million. Strong sequential increase in AviClear revenue, driven by a business model shift in North America and a successful initiation of the International limited commercial release, during the first quarter of.

Cutera Announces First Quarter 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. Participants can register for the conference call at the.

Cutera to Announce First Quarter Results on May 9, 2024

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation. The xeo+ offers providers updated features and newly redesigned handpieces that allow for faster treatment times, optimized ease of use and an improved treatment experience. "xeo® has played a pivotal role in.

News for Cutera Stock (CUTR)